Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Talc pleurodesis

INTRODUCTION

Pleurodesis is a procedure performed to obliterate the pleural space to prevent recurrent pleural effusion or pneumothorax or to a treat persistent pneumothorax. Pleurodesis is commonly accomplished by draining the pleural fluid, when present, followed by either a mechanical procedure (ie, abrasion, or (partial) pleurectomy) or instillation of a chemical irritant into the pleural space, which causes inflammation and fibrosis. Talc pleurodesis is a specific form of chemical pleurodesis. Talc is the most effective sclerosant available for pleurodesis in malignant pleural effusion [1]. As compared to indwelling pleural catheter placement, talc pleurodesis has been shown to be equally effective in relieving dyspnea [2].

This topic will review the indications, contraindications, patient selection, procedure, and outcomes of talc pleurodesis. Discussions of the management of malignant and refractory nonmalignant pleural effusions and an overview of chemical pleurodesis are provided separately. (See "Management of malignant pleural effusions" and "Management of refractory nonmalignant pleural effusions" and "Chemical pleurodesis".)

WHAT IS TALC

Talc is predominantly hydrated magnesium silicate (Mg3Si4O10(OH)2), and was first used for pleurodesis in 1935 [3]. Varying amounts of calcium, aluminum, and iron may be present, according to the origin of the formulation. Talc may also contain several mineral contaminants (eg, magnesite, dolomite, kaolinite, calcite, chlorite, serpentine, and quartz); medicinal talc is asbestos free [4].

Particle size — Talc preparations with a high proportion of particles <5 to 10 micron in diameter are associated with more severe local and systemic inflammatory responses [5,6] and with a poorer outcome [7]. However, formal standards for talc production for pleurodesis are lacking, and there is a wide variation in composition and particle size in the various talc preparations used worldwide [8].

  • In the USA, talc pleurodesis approved by the Food and Drug Administration is provided in two forms: sterile talc powder and as a talc aerosol canister with two delivery tubes (4 gm of talc per tube) that use dichlorofluoromethane (CFC-12) as a propellant. The particle size distribution for the FDA approved talc has not been disclosed by the manufacturer.
  • In Europe, commercial talc for pleurodesis is manufactured by Novatech (La Ciotat, France), and comes in four forms: Steritalc F2 (2 grams of sterile talc powder in a glass vial), Steritalc F4 (4 grams of sterile talc powder in a glass vial), Steritalc Spray (3 grams in a spray canister with propellant gas), and Steritalc PF4 spray (4 grams in a hand/air-driven pump). The French Novatech talc (not approved for use in the USA) is size-calibrated with a median particle diameter of 31.3 microns.

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Aug 1, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 2013; 19:374.
  2. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307:2383.
  3. Bethune, N. Pleural poudrage: new technique for the deliberate production of pleural adhesion as preliminary to lobectomy. J Thorac Surg 1935; 4:251.
  4. Ferrer J, Villarino MA, Tura JM, et al. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119:1901.
  5. Noppen M. Who's (still) afraid of talc? Eur Respir J 2007; 29:619.
  6. Rossi VF, Vargas FS, Marchi E, et al. Acute inflammatory response secondary to intrapleural administration of two types of talc. Eur Respir J 2010; 35:396.
  7. Arellano-Orden E, Romero-Falcon A, Juan JM, et al. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration 2013; 86:201.
  8. Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics (Sao Paulo) 2007; 62:627.
  9. Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2023.
  10. Ghio AJ, Roggli V, Light RW. Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. Am J Respir Crit Care Med 2001; 164:1741; author reply 1741.
  11. Noppen M, De Keukeleire T. Pneumothorax. Respiration 2008; 76:121.
  12. Tschopp JM, Boutin C, Astoul P, et al. Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study. Eur Respir J 2002; 20:1003.
  13. Noppen M, Meysman M, d'Haese J, et al. Comparison of video-assisted thoracoscopic talcage for recurrent primary versus persistent secondary spontaneous pneumothorax. Eur Respir J 1997; 10:412.
  14. Doddoli C, Barlési F, Fraticelli A, et al. Video-assisted thoracoscopic management of recurrent primary spontaneous pneumothorax after prior talc pleurodesis: a feasible, safe and efficient treatment option. Eur J Cardiothorac Surg 2004; 26:889.
  15. Steger V, Mika U, Toomes H, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83:1940.
  16. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10:1648.
  17. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117:87.
  18. Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157:1441.
  19. Teixeira LR, Vargas FS, Acencio MM, et al. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005; 128:4041.
  20. Liao H, Guo Y, Jun Na M, et al. The short-term administration of Ketoprofen does not decrease the effect of Pleurodesis induced by talc or Doxycycline in rabbits. Respir Med 2007; 101:963.
  21. Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg 1996; 62:1000.
  22. Colt HG, Russack V, Chiu Y, et al. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. Chest 1997; 111:442.
  23. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655.
  24. Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg 2006; 30:827.
  25. Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909.
  26. Debeljak A, Kecelj P, Triller N, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON 2006; 11:463.
  27. Terra RM, Junqueira JJ, Teixeira LR, et al. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest 2009; 136:361.
  28. Lee P, Colt HG. A spray catheter technique for pleural anesthesia: a novel method for pain control before talc poudrage. Anesth Analg 2007; 104:198.
  29. Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. Chest 2003; 123:1895.
  30. Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006; 54:51.
  31. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29:829.
  32. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; :CD002916.
  33. Laisaar T, Palmiste V, Vooder T, Umbleja T. Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis. Interact Cardiovasc Thorac Surg 2006; 5:307.
  34. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996; 110:1387.
  35. Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.
  36. Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.
  37. Lee P, Yap WS, Pek WY, Ng AW. An Audit of medical thoracoscopy and talc poudrage for pneumothorax prevention in advanced COPD. Chest 2004; 125:1315.
  38. Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377.
  39. Ferrer J, Montes JF, Villarino MA, et al. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002; 122:1018.
  40. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369:1535.
  41. Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010; 137:1375.
  42. Hunt I, Barber B, Southon R, Treasure T. Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax? Interact Cardiovasc Thorac Surg 2007; 6:117.
  43. Györik S, Erni S, Studler U, et al. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29:757.